A recent study observed differences in oral microbiome between patients with early rheumatoid arthritis (RA) or at high-risk of the disease compared to controls. Reporting in Arthritis & Rheumatology, the authors of this study concluded, “The results show similarities in the oral microbiome between early RA patients and at‐risk individuals, both presenting with increased relative abundance of potentially pro‐inflammatory species compared to healthy controls, suggesting a possible association between the oral microbiome and RA onset.”
In another study of patients with autoimmune diseases, it was found that a patient support program may be instrumental in helping patients with pain reduce or eliminate their opioid use. “This research demonstrates that the addition of a multi-faceted patient support program along with specialty medication led to better patient-centered outcomes when compared to the use of medication alone,” said first study author Mark Fendrick, MD, professor of internal medicine at the University of Michigan and director of the Center for Value Based Insurance Design.
Finally, researchers compared ustekinumab versus other biologics and apremilast for risk of serious infection requiring hospitalization among patients with psoriasis (PsO) or psoriatic arthritis (PsA). “Other biologics and apremilast were associated with 1.4‐ to 3‐times higher risk of hospitalized serious infections in PsO/PsA patients when compared with ustekinumab; such safety profile should be considered when selecting appropriate treatment regimens in patients with PsO/PsA,” the study authors wrote in their conclusion.
In Case You Missed It